CRISPR Therapeutics AG (CRSP)

NGM – Цена в реальном времени. Валюта: USD

53.87

-0.20 (-0.38%)

Рынок открыт: Aug 12, 2026, 2:25 PM EDT

53.80

-0.27 (-0.50%)

Предыдущая сессия: Aug 11, 2026, 7:59 PM EDT

05.08.2026

CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310

CRISPR Therapeutics (CRSP) remains a "Strong Buy," supported by robust CASGEVY sales growth and pipeline expansion. CASGEVY achieved $76 million Q2 2026 sales, up 151% YoY, and now targets SCD and TDT patients as young as 2 years old. CTX310 demonstrated promising phase 1 results in lipid disorders, with key data updates expected at ESC Congress and in H2 2026.

04.08.2026

CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates

CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.

03.08.2026

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $1.29 per share a year ago.

03.08.2026

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026.

Видео

No Data

There is no data to display

Пресс-релизы

03.08.2026

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026.

CRISPR Therapeutics AG (CRSP)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

CRISPR Therapeutics AG (CRSP)

CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310

CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

Видео

No Data

Пресс-релизы

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310

CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

Видео

No Data

Пресс-релизы

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

Search stocks

CRISPR Therapeutics AG (CRSP)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

CRISPR Therapeutics AG (CRSP)

CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310

CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

Видео

No Data

Пресс-релизы

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310

CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

Видео

No Data

Пресс-релизы

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results